Podium to Practice: Chicago 2026 – GI: RASolute 302 study
OR
Studies / Trials Discussed
LBA5 – Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study.
Chair
Speakers
Explore more from your favourite experts – click their name to access their entire library of content.
Studies/trials discussed:
LBA5 – Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study.
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.